Cytoreductive Surgery and HIPEC in Peritoneal Malignancies

Cytoreductive Surgery and HIPEC in Peritoneal Malignancies

Peritoneal malignancies can be difficult to treat. These cancers affect the lining of the abdominal cavity. They may develop from the peritoneum itself. However, they can also spread from organs such as the colon, appendix, stomach, ovaries, and other abdominal structures.

Traditionally, systemic chemotherapy has remained a major treatment option. However, some patients may benefit from a combined surgical approach. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is one such strategy.

What Is Cytoreductive Surgery?

Cytoreductive surgery aims to remove visible tumor deposits from the abdominal cavity. The surgeon carefully examines the peritoneal surfaces during the procedure. Then, the team removes affected tissues and organs when necessary.

The goal is to achieve complete or near-complete tumor removal. Therefore, patient selection plays a major role.

The procedure can be extensive. It may involve peritonectomy and removal of affected organs. Depending on tumor location, surgeons may remove portions of the colon, small intestine, spleen, gallbladder, or other structures.

What Is HIPEC?

HIPEC stands for hyperthermic intraperitoneal chemotherapy.

After cytoreductive surgery, the medical team circulates heated chemotherapy within the abdominal cavity. The treatment usually remains concentrated inside the peritoneal space.

Heat may enhance the activity of certain chemotherapy agents. Moreover, direct drug delivery allows high local exposure while limiting some systemic exposure.

The exact drug, dose, temperature, and duration depend on the cancer type and institutional protocol.

Why Combine CRS With HIPEC?

Surgery can remove visible disease. However, microscopic cancer cells may remain after resection.

HIPEC attempts to target these residual cells. Thus, CRS and HIPEC can address both visible and microscopic peritoneal disease.

However, the combination is not appropriate for every patient. The potential benefit depends on tumor biology, disease distribution, overall health, and the possibility of achieving adequate cytoreduction.

Patient Selection

Careful selection remains one of the most important aspects of treatment.

Doctors usually consider several factors. These include:

• Primary tumor type
• Extent of peritoneal disease
• Location of tumor deposits
• Possibility of complete cytoreduction
• Response to previous treatment
• General physical condition
• Nutritional status
• Presence of disease outside the abdominal cavity

The Peritoneal Cancer Index (PCI) can help quantify the extent of peritoneal disease. A higher PCI generally indicates more extensive disease. Therefore, PCI can contribute to treatment planning.

Major Indications

CRS with HIPEC has been studied extensively in selected peritoneal malignancies.

These include pseudomyxoma peritonei, selected colorectal cancers with peritoneal metastases, and certain peritoneal mesotheliomas. Its role can vary considerably between cancer types.

For example, treatment strategies for appendiceal tumors can differ from those used for colorectal or gastric cancers.

Therefore, clinicians should evaluate each disease separately.

Surgical Complexity

CRS with HIPEC is a major procedure. It can require several hours of surgery.

The operation may involve multiple resections. Consequently, postoperative recovery can take time.

Patients may experience complications such as:

• Infection
• Bleeding
• Anastomotic leakage
• Bowel complications
• Kidney problems
• Respiratory complications
• Electrolyte disturbances
• Prolonged hospital stay

For this reason, experienced multidisciplinary teams are essential.

Role of Multidisciplinary Care

Successful treatment requires more than surgery.

Surgical oncologists, medical oncologists, radiologists, pathologists, anesthesiologists, nutrition specialists, and intensive-care teams may all contribute.

Moreover, imaging helps determine disease distribution before surgery. Pathology provides information about tumor biology. Medical oncology also helps determine systemic treatment before or after surgery.

Therefore, multidisciplinary assessment improves treatment planning.

CRS and HIPEC Versus Systemic Therapy

Systemic chemotherapy circulates throughout the body. In contrast, HIPEC delivers chemotherapy directly into the abdominal cavity.

However, HIPEC cannot replace systemic treatment in every situation. Some cancers may require chemotherapy or targeted therapy because microscopic disease can exist beyond the peritoneal cavity.

Thus, modern treatment often combines different approaches according to individual disease characteristics.

Emerging Role of Minimally Invasive Techniques

Traditional CRS with HIPEC usually involves open surgery. However, selected centers have explored laparoscopic and robotic approaches.

These techniques may reduce surgical trauma in carefully selected patients. Nevertheless, complex disease may still require open surgery.

Therefore, minimally invasive CRS and HIPEC should only be considered when the surgical team can achieve appropriate oncological clearance.

Future Directions

Research continues to refine CRS and HIPEC.

Researchers are studying better patient-selection methods. They are also evaluating new chemotherapy agents and treatment schedules.

Furthermore, molecular biomarkers may help identify patients who are more likely to benefit. Imaging techniques are also improving disease assessment.

Artificial intelligence could eventually support treatment planning. In addition, circulating tumor DNA may provide information about residual disease and recurrence risk.

Conclusion

Cytoreductive surgery combined with HIPEC has become an important treatment strategy for selected peritoneal malignancies. The approach targets visible tumor deposits through surgery. It then targets residual microscopic disease with heated intraperitoneal chemotherapy.

However, the treatment is complex. It also carries significant risks. Therefore, careful patient selection remains essential.

Ultimately, the best outcomes depend on tumor biology, disease extent, complete cytoreduction, appropriate systemic therapy, and experienced multidisciplinary care.